Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia

Department of Haematology,Imperial College Academic Health Science Centre, Hammersmith Hospital, Du Cane Rd., London, UK.
British Journal of Haematology (Impact Factor: 4.71). 03/2011; 153(2):179-90. DOI: 10.1111/j.1365-2141.2011.08603.x
Source: PubMed


Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain reaction (RT-qPCR) is the most sensitive routine approach for monitoring the response to therapy of patients with chronic myeloid leukaemia. In the context of tyrosine kinase inhibitor (TKI) therapy, the technique is most appropriate for patients who have achieved complete cytogenetic remission and can be used to define specific therapeutic milestones. To achieve this effectively, standardization of the laboratory procedures and the interpretation of results are essential. We present here consensus best practice guidelines for RT-qPCR testing, data interpretation and reporting that have been drawn up and agreed by a consortium of 21 testing laboratories in the United Kingdom and Ireland in accordance with the procedures of the UK Clinical Molecular Genetics Society.

Download full-text


Available from: Gareth Gerrard,
  • Source
    • "RT-qPCR is an important tool that may assist in the understanding of the molecular events underlying human diseases, but it also offers a method for measuring biomarkers for the identification and stratification of a range of diseases [32, 84]. Studies have reported applying RT-qPCR for the identification of micrometastases or minimal residual disease in colorectal cancer [85], neuroblastoma [86], prostate cancer [87] and leukaemia [88]. It has been used to distinguish different types of lymphoma [89], for the analysis of cellular immune responses in the peripheral blood [90, 91], for the detection of bacterial [92] and viral [93] RNA signatures in clinical samples and for monitoring the response of human cancer to treatment [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Reverse transcription quantitative PCR is an established, simple and effective method for RNA measurement. However, technical standardisation challenges combined with frequent insufficient experimental detail render replication of many published findings challenging. Consequently, without adequate consideration of experimental standardisation, such findings may be sufficient for a given publication but cannot be translated to wider clinical application. This article builds on earlier standardisation work and the MIQE guidelines, discussing processes that need consideration for accurate, reproducible analysis when dealing with patient samples. By applying considerations common to the science of measurement (metrology), one can maximise the impact of gene expression studies, increasing the likelihood of their translation to clinical tools. ᅟ
    Analytical and Bioanalytical Chemistry 05/2014; 406(26). DOI:10.1007/s00216-014-7857-x · 3.44 Impact Factor
  • Source
    • "BCR - ABL1 transcripts were measured in whole blood for minimal residual disease monitoring using reverse transcrip - tion qPCR ( RT - qPCR ) using ABL1 as a reference gene , as reported previously ( Foroni et al , 2011 ; Gerrard et al , 2011 ) . SLC22A1 and BCR - ABL1 transcript levels , as well as those of two control genes : beta2 - microglobulin ( B2M ) and beta - glucuronidase ( GUSB ) , were quantified using pre - treatment diagnostic cDNA from whole blood leucocytes by RT - qPCR using a Taqman system on a StepOnePlus ( "
    [Show abstract] [Hide abstract]
    ABSTRACT: Approximately one-third of patients with chronic myeloid leukaemia will fail to achieve or maintain responses to imatinib. Changes in solute carrier family 22 (organic cation transporter), member 1 (SLC22A1, also termed OCT1), the main transporter for imatinib, have been proposed as a possible predictive factor. We analysed SLC22A1 mRNA levels and single nucleotide polymorphisms (SNPs) located in exon 7 in 153 diagnostic whole blood samples from two patient cohorts. The level of SLC22A1 expression did not significantly correlate with imatinib failure or achievement of molecular remission. The SNP 408V>M (g.1222G>A) was present in 65% of patients and was associated in all cases with an eight base-pair insertion (8(+) allele) at the 3' end of exon 7. The latter generates an alternative splice site, leading to a premature stop codon. M420del was found in 33% of patients and never in cis with 8(+) (the 3(-) allele). Significantly longer times to 1% and 0·1% molecular responses (by quantitative reverse transcription polymerase chain reaction) were seen in patients with 8(+) 8(+) or 8(+) N compared to those with the remaining four genotypes (N = no insertion or deletion). Patients lacking 8(+) and 3(-) (NN, 18%) showed the best outcomes overall. Thus, while SLC22A1 expression does not appear to affect response, alterations in its splicing or amino acid sequence may do so.
    British Journal of Haematology 10/2013; 163(5). DOI:10.1111/bjh.12591 · 4.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In these last years of revolutionary tyrosine kinase inhibitor treatments, patients with chronic myeloid leukemia are most commonly monitored by regular examination of bone marrow and peripheral blood in order to assess the quality of the response to treatment. Biological criteria and adapted methodologies in cytogenetics and molecular biology have been established from clinical trials. To date, it is essential to know these criteria for an optimal therapeutic management of these patients, in order to guarantee a better overall survival and an event-free survival.
    Oncologie 10/2012; 14(10-11). DOI:10.1007/s10269-012-2212-3 · 0.06 Impact Factor
Show more